Stanford University’s Innovative Medicines Accelerator (IMA) and Intonation Research Laboratories have partnered to develop targeted treatments for neuroendocrine tumors, aiming to accelerate drug development and reduce costs. 

“This collaboration has the potential to transform research into urgently needed therapies,” said Stanford President Marc Tessier-Lavigne. 

Led by founder and chairman Suresh K. Jain, PhD, Intonation will work with Stanford researchers to refine key discoveries. “Partnering with Stanford’s IMA will enhance drug discovery in India,” Jain said. 

The partnership strengthens Stanford’s mission to accelerate biomedical breakthroughs into real-world treatments.